# A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma

> **NCT06999031** · EARLY_PHASE1 · RECRUITING · sponsor: **The First Affiliated Hospital of Nanchang University** · enrollment: 12 (estimated)

## Conditions studied

- Relapsed/Refractory
- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** BCMA-Targeted Chimeric Antigen Receptor Autologous T-cell

## Key facts

- **NCT ID:** NCT06999031
- **Lead sponsor:** The First Affiliated Hospital of Nanchang University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-05
- **Primary completion:** 2026-04-05
- **Final completion:** 2027-09-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-05-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06999031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06999031, "A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06999031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*